Cytokinetics (NASDAQ:CYTK) CEO Robert I. Blum sold 4,000 shares of the firm’s stock in a transaction on Friday, May 4th. The shares were sold at an average price of $8.38, for a total transaction of $33,520.00. Following the completion of the transaction, the chief executive officer now owns 183,722 shares in the company, valued at $1,539,590.36. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of Cytokinetics stock opened at $8.50 on Friday. The company has a quick ratio of 8.46, a current ratio of 7.07 and a debt-to-equity ratio of 0.32. Cytokinetics has a fifty-two week low of $6.75 and a fifty-two week high of $15.95. The firm has a market capitalization of $459.07, a price-to-earnings ratio of -3.28 and a beta of 1.13.
Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.06). Cytokinetics had a negative net margin of 172.27% and a negative return on equity of 99.50%. The company had revenue of $5.27 million during the quarter, compared to the consensus estimate of $5.50 million. equities research analysts expect that Cytokinetics will post -2.07 earnings per share for the current fiscal year.
A number of research analysts recently issued reports on CYTK shares. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Cytokinetics in a research note on Friday, April 27th. BidaskClub raised shares of Cytokinetics from a “strong sell” rating to a “sell” rating in a report on Tuesday, March 6th. ValuEngine raised shares of Cytokinetics from a “sell” rating to a “hold” rating in a report on Friday, April 27th. Cantor Fitzgerald set a $10.00 price target on shares of Cytokinetics and gave the company a “hold” rating in a report on Tuesday, April 24th. Finally, Cowen reissued a “buy” rating and issued a $11.00 price target on shares of Cytokinetics in a report on Tuesday, February 20th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $15.67.
Several large investors have recently added to or reduced their stakes in CYTK. Wells Fargo & Company MN lifted its holdings in shares of Cytokinetics by 48.7% during the 3rd quarter. Wells Fargo & Company MN now owns 50,523 shares of the biopharmaceutical company’s stock worth $733,000 after acquiring an additional 16,555 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in shares of Cytokinetics by 8.3% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 303,347 shares of the biopharmaceutical company’s stock worth $4,399,000 after acquiring an additional 23,142 shares during the period. GSA Capital Partners LLP bought a new position in shares of Cytokinetics during the 3rd quarter worth about $187,000. Wasatch Advisors Inc. lifted its holdings in shares of Cytokinetics by 139.1% during the 4th quarter. Wasatch Advisors Inc. now owns 1,679,778 shares of the biopharmaceutical company’s stock worth $13,690,000 after acquiring an additional 977,106 shares during the period. Finally, Fox Run Management L.L.C. bought a new position in shares of Cytokinetics during the 4th quarter worth about $181,000. 71.25% of the stock is owned by institutional investors.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.